Literature DB >> 20127053

Celastrol and an EGCG pro-drug exhibit potent chemosensitizing activity in human leukemia cells.

Andrew Davenport1, Michael Frezza, Min Shen, Yubin Ge, Congde Huo, Tak Hang Chan, Q Ping Dou.   

Abstract

Chemotherapy remains the staple of treatment for many types of leukemia. Despite the positive impact on extending overall survival in patients with hematological malignancies, new treatment strategies are needed to reduce the nonspecific toxicity and improve the efficacy of treatment. Celastrol, derived from the 'Thunder God Vine' and Pro-EGCG, a pre-drug version of green tea polyphenol EGCG have shown potent biological activity in vitro and in vivo. Whether these natural products augment the efficacy of conventional chemotherapy in the treatment of leukemia cells has yet to be demonstrated. Here we demonstrate that these natural products could sensitize the effect of chemotherapy in both K-562 and Jurkat T human leukemia cells. Accordingly, this potent biological activity was associated with increased levels of leukemia cell killing, caspase 3 activation, and poly(ADP-ribose) polymerase cleavage. Furthermore, the higher levels of apoptotic indices were associated with decreased levels of Bcr-Abl oncoprotein in K-562 cells. Taken together, our findings present a compelling rationale for the development of combination strategies using natural products in the treatment of hematological malignancies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20127053      PMCID: PMC3304460          DOI: 10.3892/ijmm_00000366

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  26 in total

1.  Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo.

Authors:  S Nam; D M Smith; Q P Dou
Journal:  J Biol Chem       Date:  2001-01-26       Impact factor: 5.157

2.  Apoptosis. Life and death decisions.

Authors:  Donald W Nicholson; Nancy A Thornberry
Journal:  Science       Date:  2003-01-10       Impact factor: 47.728

Review 3.  Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics.

Authors:  Fazlul H Sarkar; Yiwei Li
Journal:  Cancer Treat Rev       Date:  2009-08-05       Impact factor: 12.111

Review 4.  Green tea: cancer preventive beverage and/or drug.

Authors:  Hirota Fujiki; Masami Suganuma; Kazue Imai; Kei Nakachi
Journal:  Cancer Lett       Date:  2002-12-15       Impact factor: 8.679

5.  Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol.

Authors:  Masahiro Nagase; Jinsei Oto; Sin Sugiyama; Kouichi Yube; Yoshihisa Takaishi; Nobuo Sakato
Journal:  Biosci Biotechnol Biochem       Date:  2003-09       Impact factor: 2.043

6.  Celastrol inhibits pro-inflammatory cytokine secretion in Crohn's disease biopsies.

Authors:  Guillaume F Pinna; Marc Fiorucci; Jean-Marie Reimund; Nathalie Taquet; Yves Arondel; Christian D Muller
Journal:  Biochem Biophys Res Commun       Date:  2004-09-24       Impact factor: 3.575

7.  A potential prodrug for a green tea polyphenol proteasome inhibitor: evaluation of the peracetate ester of (-)-epigallocatechin gallate [(-)-EGCG].

Authors:  Wai Har Lam; Aslamuzzaman Kazi; Deborah J Kuhn; Larry M C Chow; Albert S C Chan; Q Ping Dou; Tak Hang Chan
Journal:  Bioorg Med Chem       Date:  2004-11-01       Impact factor: 3.641

8.  Cleavage of retinoblastoma protein during apoptosis: an interleukin 1 beta-converting enzyme-like protease as candidate.

Authors:  B An; Q P Dou
Journal:  Cancer Res       Date:  1996-02-01       Impact factor: 12.701

9.  Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia.

Authors:  Merat Karbasian-Esfahani; Peter H Wiernik; Yelena Novik; Elisabeth Paietta; Janice P Dutcher
Journal:  Cancer       Date:  2004-09-15       Impact factor: 6.860

10.  Antitumor agents. 228. five new agarofurans, Reissantins A-E, and cytotoxic principles from Reissantia buchananii.

Authors:  Fang-Rong Chang; Ken-Ichiro Hayashi; I-Hsiao Chen; Chih-Chuang Liaw; Kenneth F Bastow; Yuka Nakanishi; Hiroshi Nozaki; Gordon M Cragg; Yang-Chang Wu; Kuo-Hsiung Lee
Journal:  J Nat Prod       Date:  2003-11       Impact factor: 4.050

View more
  16 in total

Review 1.  Targeting tumor ubiquitin-proteasome pathway with polyphenols for chemosensitization.

Authors:  Min Shen; Tak Hang Chan; Q Ping Dou
Journal:  Anticancer Agents Med Chem       Date:  2012-10-01       Impact factor: 2.505

Review 2.  Therapy-related acute myeloid leukemia and its prevention.

Authors:  Gennady Belitsky; Timur Fetisov; Kirill Kirsanov; Ekaterina Lesovaya; Olga Vlasova; Marianna Yakubovskaya
Journal:  Am J Blood Res       Date:  2020-12-15

3.  A derivative of epigallocatechin-3-gallate induces apoptosis via SHP-1-mediated suppression of BCR-ABL and STAT3 signalling in chronic myelogenous leukaemia.

Authors:  Ji Hoon Jung; Miyong Yun; Eun-Jeong Choo; Sun-Hee Kim; Myoung-Seok Jeong; Deok-Beom Jung; Hyemin Lee; Eun-Ok Kim; Nobuo Kato; Bonglee Kim; Sanjay K Srivastava; Kunihiro Kaihatsu; Sung-Hoon Kim
Journal:  Br J Pharmacol       Date:  2015-06-04       Impact factor: 8.739

Review 4.  Synergistic enhancement of anticancer effects on numerous human cancer cell lines treated with the combination of EGCG, other green tea catechins, and anticancer compounds.

Authors:  Hirota Fujiki; Eisaburo Sueoka; Tatsuro Watanabe; Masami Suganuma
Journal:  J Cancer Res Clin Oncol       Date:  2014-12-28       Impact factor: 4.553

5.  Dual properties of hispidulin: antiproliferative effects on HepG2 cancer cells and selective inhibition of ABCG2 transport activity.

Authors:  Carina T Scoparo; Glaucio Valdameri; Paulo R Worfel; Fernanda A L B Guterres; Glaucia R Martinez; Sheila M B Winnischofer; Attilio Di Pietro; Maria E M Rocha
Journal:  Mol Cell Biochem       Date:  2015-07-26       Impact factor: 3.396

Review 6.  Green Tea Epigallocatechin-3-Gallate Regulates Autophagy in Male and Female Reproductive Cancer.

Authors:  Sze Wan Hung; Yiran Li; Xiaoyan Chen; Kai On Chu; Yiwei Zhao; Yingyu Liu; Xi Guo; Gene Chi-Wai Man; Chi Chiu Wang
Journal:  Front Pharmacol       Date:  2022-07-04       Impact factor: 5.988

7.  Development of B cells and erythrocytes is specifically impaired by the drug celastrol in mice.

Authors:  Sophie Kusy; Eliver E B Ghosn; Leonore A Herzenberg; Christopher H Contag
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

Review 8.  Broad targeting of resistance to apoptosis in cancer.

Authors:  Ramzi M Mohammad; Irfana Muqbil; Leroy Lowe; Clement Yedjou; Hsue-Yin Hsu; Liang-Tzung Lin; Markus David Siegelin; Carmela Fimognari; Nagi B Kumar; Q Ping Dou; Huanjie Yang; Abbas K Samadi; Gian Luigi Russo; Carmela Spagnuolo; Swapan K Ray; Mrinmay Chakrabarti; James D Morre; Helen M Coley; Kanya Honoki; Hiromasa Fujii; Alexandros G Georgakilas; Amedeo Amedei; Elena Niccolai; Amr Amin; S Salman Ashraf; William G Helferich; Xujuan Yang; Chandra S Boosani; Gunjan Guha; Dipita Bhakta; Maria Rosa Ciriolo; Katia Aquilano; Sophie Chen; Sulma I Mohammed; W Nicol Keith; Alan Bilsland; Dorota Halicka; Somaira Nowsheen; Asfar S Azmi
Journal:  Semin Cancer Biol       Date:  2015-04-28       Impact factor: 15.707

Review 9.  Celastrol: A Spectrum of Treatment Opportunities in Chronic Diseases.

Authors:  Rita Cascão; João E Fonseca; Luis F Moita
Journal:  Front Med (Lausanne)       Date:  2017-06-15

10.  Metabolomics profiles delineate uridine deficiency contributes to mitochondria-mediated apoptosis induced by celastrol in human acute promyelocytic leukemia cells.

Authors:  Xiaoling Zhang; Jing Yang; Minjian Chen; Lei Li; Fei Huan; Aiping Li; Yanqing Liu; Yankai Xia; Jin-Ao Duan; Shiping Ma
Journal:  Oncotarget       Date:  2016-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.